Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin™) to chemotherapy improves survival in metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 3, Issue 2, 2003, Pages 85-88

  D'Orazio, Amy ^b   Lee, David ^b   Ellis, Lee ^b   Chu, Edward ^a  

^a YALE CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; PLACEBO; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BLEEDING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; METASTASIS POTENTIAL; NEUTROPENIA; PROTEIN FUNCTION; PROTEINURIA; SENSORY NEUROPATHY; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT OUTCOME; VOMITING;

EID: 0041381022     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1533-0028(11)70071-8     Document Type: Article

References (8)

1. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77:527-543.
2. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000; 5:3-10.
3. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001; 19:851-856.
4. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-65.
5. Hurwitz HI, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. 39th Annual Meeting of the American Society of Clinical Oncology: Late Breaking Abstract #2646; Chicago, IL, 2003.
6. Giantonio BJ, Levy D, O'Dwyer PJ, et al. Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): Results from the Eastern Cooperative Oncology Group (ECOG) Study E2200. Proc Am Soc Clin Oncol 2003; 22:255 (Abstract #1024).
7. Benson A, Catalano P, Meropol NJ, et al. Bevacizumab (anti-VEGF) plus FOLFOX4 in previously untreated advanced colorectal cancer (advCRC): an interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol 2003; 22:243 (Abstract #975).
8. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study. Proc Am Soc Clin Oncol 2003; 22:252 (Abstract #1009).